RESUMEN
Staphylococcus aureus is a prevalent pathogen in pneumonia and harbors glycolipids, which may serve as molecular patterns in Mincle (macrophage-inducible C-type lectin)-dependent pathogen recognition. We examined the role of Mincle in lung defense against S aureus in wild-type (WT), Mincle knockout (KO), and Mincle transgenic (tg) mice. Two glycolipids, glucosyl-diacylglycerol (Glc-DAG) and diglucosyl-diacylglycerol (Glc2-DAG), were purified, of which only Glc-DAG triggered Mincle reporter cell activation and professional phagocyte responses. Proteomic profiling revealed that Glc2-DAG blocked Glc-DAG-induced cytokine responses, thereby acting as inhibitor of Glc-DAG/Mincle signaling. WT mice responded to S aureus with a similar lung pathology as Mincle KO mice, most likely due to Glc2-DAG-dependent inhibition of Glc-DAG/Mincle signaling. In contrast, ectopic Mincle expression caused severe lung pathology in S aureus-infected mice, characterized by bacterial outgrowth and fatal pneumonia. Collectively, Glc2-DAG inhibits Glc-DAG/Mincle-dependent responses in WT mice, whereas sustained Mincle expression overrides Glc2-DAG-mediated inhibitory effects, conferring increased host susceptibility to S aureus.
Asunto(s)
Lectinas Tipo C , Proteínas de la Membrana , Ratones Noqueados , Neumonía Estafilocócica , Staphylococcus aureus , Animales , Lectinas Tipo C/metabolismo , Lectinas Tipo C/genética , Neumonía Estafilocócica/microbiología , Neumonía Estafilocócica/inmunología , Ratones , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Pulmón/microbiología , Pulmón/patología , Ratones Transgénicos , Ratones Endogámicos C57BL , Transducción de Señal , Susceptibilidad a Enfermedades , Citocinas/metabolismoRESUMEN
BACKGROUND: Previous researches have clarified that miR-155 is increased in methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, and modulates Th9 differentiation. Like Th9 cells, Th17 cells were also a subset of CD4+ T cells and involved in MRSA pneumonia progression. This work aimed to investigate the role and mechanism of miR-155 in Th17 differentiation. METHODS: Bronchoalveolar lavage fluid (BALF) was collected from children with MRSA pneumonia and bronchial foreign bodies. MRSA-infected murine model was established followed by collecting BALF and lung tissues. qRT-PCR, ELISA and flow cytometry were performed to examine the mRNA expression and concentration of IL-17 and the number of Th17 cells in above samples. HE and ELISA were used to evaluate inflammatory responses in lung. Furthermore, CD4+ T cells were isolated from BALF of children for in vitro experiments. After treatments with miR-155 mimic/inhibitor, the roles of miR-155 in Th17/IL-17 regulation were determined. The downstream of miR-155 was explored by qRT-PCR, western blotting, dual luciferase reporter analysis and RIP assay. RESULTS: The levels of IL-17 and the proportion of Th17 cells were increased in children with MRSA pneumonia. A similar pattern was observed in MRSA-infected mice. On the contrary, IL-17 neutralization abolished the activation of Th17/IL-17 induced by MRSA infection. Furthermore, IL-17 blockade diminished the inflammation caused by MRSA. In vitro experiments demonstrated miR-155 positively regulated IL-17 expression and Th17 differentiation. Mechanistically, FOXP3 was a direct target of miR-155. miR-155 inhibited FOXP3 level via binding between FOXP3 and Argonaute 2 (AGO2), the key component of RNA-induced silencing complex (RISC). FOXP3 overexpression reversed elevated IL-17 levels and Th17 differentiation induced by miR-155. CONCLUSIONS: miR-155 facilitates Th17 differentiation by reducing FOXP3 through interaction of AGO2 and FOXP3 to promote the pathogenesis of MRSA pneumonia. IL-17 blockade weakens the inflammation due to MRSA, which provides a nonantibiotic treatment strategy for MRSA pneumonia.
Asunto(s)
Diferenciación Celular , Factores de Transcripción Forkhead , Inflamación , Interleucina-17 , Staphylococcus aureus Resistente a Meticilina , MicroARNs , Células Th17 , MicroARNs/genética , MicroARNs/metabolismo , Células Th17/inmunología , Células Th17/metabolismo , Animales , Factores de Transcripción Forkhead/metabolismo , Factores de Transcripción Forkhead/genética , Humanos , Ratones , Interleucina-17/metabolismo , Inflamación/metabolismo , Masculino , Líquido del Lavado Bronquioalveolar , Femenino , Niño , Neumonía Estafilocócica/inmunología , Neumonía Estafilocócica/metabolismo , Neumonía Estafilocócica/microbiología , PreescolarRESUMEN
OBJECTIVE: To build and merge a diagnostic model called multi-input DenseNet fused with clinical features (MI-DenseCFNet) for discriminating between Staphylococcus aureus pneumonia (SAP) and Aspergillus pneumonia (ASP) and to evaluate the significant correlation of each clinical feature in determining these two types of pneumonia using a random forest dichotomous diagnosis model. This will enhance diagnostic accuracy and efficiency in distinguishing between SAP and ASP. METHODS: In this study, 60 patients with clinically confirmed SAP and ASP, who were admitted to four large tertiary hospitals in Kunming, China, were included. Thoracic high-resolution CT lung windows of all patients were extracted from the picture archiving and communication system, and the corresponding clinical data of each patient were collected. RESULTS: The MI-DenseCFNet diagnosis model demonstrates an internal validation set with an area under the curve (AUC) of 0.92. Its external validation set demonstrates an AUC of 0.83. The model requires only 10.24s to generate a categorical diagnosis and produce results from 20 cases of data. Compared with high-, mid-, and low-ranking radiologists, the model achieves accuracies of 78% vs. 75% vs. 60% vs. 40%. Eleven significant clinical features were screened by the random forest dichotomous diagnosis model. CONCLUSION: The MI-DenseCFNet multimodal diagnosis model can effectively diagnose SAP and ASP, and its diagnostic performance significantly exceeds that of junior radiologists. The 11 important clinical features were screened in the constructed random forest dichotomous diagnostic model, providing a reference for clinicians. CLINICAL RELEVANCE STATEMENT: MI-DenseCFNet could provide diagnostic assistance for primary hospitals that do not have advanced radiologists, enabling patients with suspected infections like Staphylococcus aureus pneumonia or Aspergillus pneumonia to receive a quicker diagnosis and cut down on the abuse of antibiotics. KEY POINTS: ⢠MI-DenseCFNet combines deep learning neural networks with crucial clinical features to discern between Staphylococcus aureus pneumonia and Aspergillus pneumonia. ⢠The comprehensive group had an area under the curve of 0.92, surpassing the proficiency of junior radiologists. ⢠This model can enhance a primary radiologist's diagnostic capacity.
Asunto(s)
Aprendizaje Profundo , Tomografía Computarizada por Rayos X , Humanos , Masculino , Femenino , Persona de Mediana Edad , Diagnóstico Diferencial , Tomografía Computarizada por Rayos X/métodos , Neumonía Estafilocócica/diagnóstico por imagen , Neumonía Estafilocócica/microbiología , Anciano , Aspergilosis Pulmonar/diagnóstico por imagen , Staphylococcus aureus/aislamiento & purificación , Adulto , Interpretación de Imagen Radiográfica Asistida por Computador/métodosRESUMEN
Existing recommended first-line antibiotic agents for MRSA pneumonia have several shortcomings. We reviewed 29 cases of community- and hospital-acquired MRSA pneumonia managed at our hospital. Lincosamide monotherapy was administered to 21/29 (72%) and was the predominant antibiotic regimen (> 50% course duration) in 19/29 (66%). Patients receiving lincosamide-predominant monotherapy were no more likely to die or require intensive care unit admission than patients receiving vancomycin-predominant monotherapy (5/19 (26%) versus 4/7 (57%), p = 0.19); 5/7 (71%) patients admitted to ICU and 4/5 (80%) bacteraemic patients received lincosamide-predominant monotherapy. MRSA pneumonia can be safely treated with lincosamide monotherapy if the isolate is susceptible.
Asunto(s)
Antibacterianos , Lincosamidas , Staphylococcus aureus Resistente a Meticilina , Neumonía Estafilocócica , Humanos , Antibacterianos/uso terapéutico , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Masculino , Femenino , Persona de Mediana Edad , Adulto , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/microbiología , Anciano , Australia/epidemiología , Lincosamidas/uso terapéutico , Lincosamidas/farmacología , Resultado del Tratamiento , Estudios Retrospectivos , Adulto Joven , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/microbiología , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Anciano de 80 o más AñosRESUMEN
Staphylococcus aureus (S. aureus) pneumonia has become an increasingly important public health problem. Recent evidence suggests that epigenetic modifications are critical in the host immune defence against pathogen infection. In this study, we found that S. aureus infection induces the expression of histone deacetylase 6 (HDAC6) in a dose-dependent manner. Furthermore, by using a S. aureus pneumonia mouse model, we showed that the HDAC6 inhibitor, tubastatin A, demonstrates a protective effect in S. aureus pneumonia, decreasing the mortality and destruction of lung architecture, reducing the bacterial burden in the lungs and inhibiting inflammatory responses. Mechanistic studies in primary bone marrow-derived macrophages demonstrated that the HDAC6 inhibitors, tubastatin A and tubacin, reduced the intracellular bacterial load by promoting bacterial clearance rather than regulating phagocytosis. Finally, N-acetyl-L- cysteine, a widely used reactive oxygen species (ROS) scavenger, antagonized ROS production and significantly inhibited tubastatin A-induced S. aureus clearance. These findings demonstrate that HDAC6 inhibitors promote the bactericidal activity of macrophages by inducing ROS, an important host factor for S. aureus clearance and production. Our study identified HDAC6 as a suitable epigenetic modification target for preventing S. aureus infection, and tubastatin A as a useful compound in treating S. aureus pneumonia.
Asunto(s)
Histona Desacetilasa 6 , Inhibidores de Histona Desacetilasas , Macrófagos , Especies Reactivas de Oxígeno , Staphylococcus aureus , Animales , Histona Desacetilasa 6/antagonistas & inhibidores , Histona Desacetilasa 6/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Staphylococcus aureus/efectos de los fármacos , Ratones , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Macrófagos/microbiología , Inhibidores de Histona Desacetilasas/farmacología , Ácidos Hidroxámicos/farmacología , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/microbiología , Neumonía Estafilocócica/metabolismo , Indoles/farmacología , Ratones Endogámicos C57BL , Fagocitosis/efectos de los fármacos , Pulmón/efectos de los fármacos , Pulmón/microbiología , Pulmón/metabolismo , Pulmón/patologíaRESUMEN
Staphylococcus aureus is a gram-positive bacteria, and its virulence factors can cause many kinds of infections, such as pneumonia, sepsis, enteritis and osteomyelitis. Traditional antibiotics can not only kill bacteria, but also easily lead to bacterial resistance. Jingfang Mixture (JFM) has the effects of inducing sweating and relieving the exterior, dispelling wind and eliminating dampness, and is commonly used in clinic to prevent and treat epidemic diseases and infectious diseases. The main purpose of this study is to explore the inhibitory effect of JFM on alpha-hemolysin (Hla) of S. aureus and to alleviate the damage caused by Hla. We found that JFM could inhibit the hemolytic activity, transcription level and neutralizing activity of Hla in a dose-dependent manner at the concentrations of 125, 250 and 500 µg/mL, without affecting the growth of bacteria. In addition, JFM reduced the damage of Hla to A549 cells and the release of lactate dehydrogenase (LDH). We also observed that in the S. aureus - induced pneumonia mouse model, JFM could significantly prolong the life of mice, reduce the bacterial load in the lungs, significantly improve the pathological state of the lungs and alleviate the damage caused by inflammatory factors, and the pathogenicity of gene deletion strain DU 1090 of S. aureus to pneumonia mice was also significantly reduced. In conclusion, this study proved that JFM is a potential drug against S. aureus infection, and this study provided a preliminary study for better guidance of clinical drug use.
Asunto(s)
Antibacterianos , Proteínas Hemolisinas , Infecciones Estafilocócicas , Staphylococcus aureus , Animales , Femenino , Humanos , Ratones , Células A549 , Antibacterianos/farmacología , Carga Bacteriana/efectos de los fármacos , Toxinas Bacterianas/genética , Toxinas Bacterianas/metabolismo , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/farmacología , Proteínas Hemolisinas/metabolismo , Hemólisis/efectos de los fármacos , Pulmón/microbiología , Pulmón/efectos de los fármacos , Ratones Endogámicos BALB C , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/microbiología , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Factores de Virulencia/genéticaRESUMEN
BACKGROUND: The optimal method for delivering phages in the context of ventilator-associated pneumonia (VAP) is unknown. In the current study, we assessed the utility of aerosolized phages (aerophages) for experimental methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. METHODS: Rats were ventilated for 4 hours before induction of pneumonia. Animals received one of the following: (1) aerophages; (2) intravenous (IV) phages; (3) a combination of IV and aerophages; (4) IV linezolid; or (5) a combination of IV linezolid and aerophages. Phages were administered at 2, 12, 24, 48, and 72 hours, and linezolid was administered at 2, 12, 24, 36, 48, 60, and 72 hours. The primary outcome was survival at 96 hours. Secondary outcomes were bacterial and phage counts in tissues and histopathological scoring of the lungs. RESULTS: Aerophages and IV phages each rescued 50% of animals from severe MRSA pneumonia (Pâ <â .01 compared with placebo controls). The combination of aerophages and IV phages rescued 91% of animals, which was higher than either monotherapy (Pâ <â .05). Standard-of-care antibiotic linezolid rescued 38% of animals. However, linezolid and aerophages did not synergize in this setting (55% survival). CONCLUSIONS: Aerosolized phage therapy showed potential for the treatment of MRSA pneumonia in an experimental animal model and warrants further investigation for application in humans.
Asunto(s)
Bacteriófagos , Staphylococcus aureus Resistente a Meticilina , Neumonía Estafilocócica , Neumonía Asociada al Ventilador , Animales , Linezolid/uso terapéutico , Neumonía Estafilocócica/microbiología , Neumonía Asociada al Ventilador/tratamiento farmacológico , RatasRESUMEN
Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). MRSA pneumonia is associated with significant morbidity and mortality. Several virulence factors allow S. aureus to become an effective pathogen. The polysaccharide intracellular adhesin allows for the production of biofilms, some strains can produce capsular polysaccharides that protect against phagocytosis, microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) allow for colonization of epithelial surfaces, and S. aureus secretes several exotoxins that aid in tissue destruction. The α-hemolysin exotoxin secreted by S. aureus is one of the most important virulence factors for the bacteria. The diagnosis of MRSA pneumonia can be challenging; the infection may present as a mild respiratory infection or severe respiratory failure and septic shock. Many individuals are colonized with MRSA and thus a positive nasopharyngeal swab does not confirm infection in the lower respiratory tract. The management of MRSA pneumonia has evolved. Historically, vancomycin has been the primary antibiotic used to treat MRSA pneumonia. Over the past decade, prospective studies have shown that linezolid leads to higher rates of clinical cure. Monoclonal antibodies are being studied as potential therapeutic options. MRSA is an important cause of HAP/VAP; novel diagnostics may facilitate rapid diagnosis of this infection and the available literature should be used to make informed decisions on management.
Asunto(s)
Infección Hospitalaria , Staphylococcus aureus Resistente a Meticilina , Neumonía Estafilocócica , Neumonía Asociada al Ventilador , Infecciones Estafilocócicas , Antibacterianos/uso terapéutico , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Exotoxinas , Hospitales , Humanos , Neumonía Estafilocócica/diagnóstico , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/microbiología , Neumonía Asociada al Ventilador/diagnóstico , Neumonía Asociada al Ventilador/tratamiento farmacológico , Neumonía Asociada al Ventilador/microbiología , Estudios Prospectivos , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Staphylococcus aureus , Factores de VirulenciaRESUMEN
Pneumonia-induced lung injury and acute respiratory distress syndrome can develop because of an inappropriate inflammatory response to acute infections, leading to a compromised alveolar barrier. Recent work suggests that hospitalized patients with allergies/asthma are less likely to die of pulmonary infections and that there is a correlation between survival from acute respiratory distress syndrome and higher eosinophil counts; thus, we hypothesized that eosinophils associated with a type 2 immune response may protect against pneumonia-induced acute lung injury. To test this hypothesis, mice were treated with the type 2-initiating cytokine IL-33 intratracheally 3 days before induction of pneumonia with airway administration of a lethal dose of Staphylococcus aureus. Interestingly, IL-33 pretreatment promoted survival by inhibiting acute lung injury: amount of BAL fluid proinflammatory cytokines and pulmonary edema were both reduced, with an associated increase in oxygen saturation. Pulmonary neutrophilia was also reduced, whereas eosinophilia was strongly increased. This eosinophilia was key to protection; eosinophil reduction eliminated both IL-33-mediated protection against mortality and inhibition of neutrophilia and pulmonary edema. Together, these data reveal a novel role for eosinophils in protection against lung injury and suggest that modulation of pulmonary type 2 immunity may represent a novel therapeutic strategy.
Asunto(s)
Lesión Pulmonar Aguda/inmunología , Eosinófilos/inmunología , Interleucina-33/inmunología , Neumonía Estafilocócica/inmunología , Edema Pulmonar/inmunología , Síndrome de Dificultad Respiratoria/inmunología , Staphylococcus aureus/patogenicidad , Lesión Pulmonar Aguda/etiología , Lesión Pulmonar Aguda/microbiología , Lesión Pulmonar Aguda/prevención & control , Animales , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Toxina Diftérica/farmacología , Modelos Animales de Enfermedad , Eosinófilos/efectos de los fármacos , Femenino , Expresión Génica , Humanos , Interleucina-33/genética , Interleucina-33/farmacología , Interleucina-5/deficiencia , Interleucina-5/genética , Interleucina-5/inmunología , Recuento de Leucocitos , Procedimientos de Reducción del Leucocitos , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neumonía Estafilocócica/complicaciones , Neumonía Estafilocócica/microbiología , Neumonía Estafilocócica/mortalidad , Edema Pulmonar/complicaciones , Edema Pulmonar/microbiología , Edema Pulmonar/mortalidad , Síndrome de Dificultad Respiratoria/etiología , Síndrome de Dificultad Respiratoria/microbiología , Síndrome de Dificultad Respiratoria/prevención & control , Staphylococcus aureus/inmunología , Análisis de SupervivenciaRESUMEN
BACKGROUND: The 2019 community-acquired pneumonia guidelines recommend using recent respiratory cultures and locally validated epidemiology plus risk factor assessment to determine empirical coverage of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. OBJECTIVE: To develop a methodology for evaluating local epidemiology and validating local risk factors for P aeruginosa and MRSA. METHODS: This multicenter, retrospective cohort evaluated adult patients admitted for pneumonia. Risk factors for MRSA and P aeruginosa were evaluated using multivariable logistic regression and reported as adjusted odds ratios (aORs). RESULTS: There were 10 723 cases evaluated. Lung abscess/empyema had the highest odds associated with MRSA (aOR = 4.24; P < 0.0001), followed by influenza (aOR = 2.34; P = 0.01), end-stage renal disease (ESRD; aOR = 2.09; P = 0.006), illicit substance use (aOR = 1.7; P = 0.007), and chronic obstructive pulmonary disease (COPD; aOR = 1.26; P = 0.04). For P aeruginosa, the highest odds were in bronchiectasis (aOR = 6.13; P < 0.0001), lung abscess/empyema (aOR = 3.36; P = 0.005), and COPD (aOR = 1.84; P < 0.0001). Isolated COPD without other risk factors did not pose an increased risk of either organism. CONCLUSION AND RELEVANCE: Influenza, ESRD, lung abscess/empyema, and illicit substance use were local risk factors for MRSA. Bronchiectasis and lung abscess/empyema were risk factors for Pseudomonas. COPD was associated with MRSA and Pseudomonas. However, isolated COPD had similar rates of MRSA and Pseudomonas pneumonia compared with the total population. This study established a feasible methodology for evaluating local risk factors.
Asunto(s)
Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Neumonía Bacteriana/etiología , Neumonía Estafilocócica/etiología , Infecciones por Pseudomonas/etiología , Pseudomonas aeruginosa/aislamiento & purificación , Adulto , Anciano , Estudios de Cohortes , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/microbiología , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neumonía Bacteriana/epidemiología , Neumonía Bacteriana/microbiología , Neumonía Estafilocócica/epidemiología , Neumonía Estafilocócica/microbiología , Infecciones por Pseudomonas/epidemiología , Infecciones por Pseudomonas/microbiología , Estudios Retrospectivos , Factores de RiesgoRESUMEN
STUDY OBJECTIVE: The objective of this study was to determine if performing a methicillin-resistant Staphylococcus aureus (MRSA) nasal screen in the emergency department (ED) decreased general medicine patient exposure to anti-MRSA antibiotics for pneumonia. METHODS: This was a single-center, retrospective study evaluating patients who had a diagnosis of pneumonia and were initiated on anti-MRSA therapy (vancomycin or linezolid) in the ED and subsequently admitted to a general medicine floor. Patients were divided into two groups: 1) did not receive a MRSA nares screen in the ED (No MRSA screen group) or 2) received a MRSA nares screen in the ED (MRSA screen group). The primary outcome was anti-MRSA antibiotic duration. Secondary outcomes included vancomycin level evaluation, hospital survival, and acute kidney injury. RESULTS: Of the 116 patients included, 37 patients received a MRSA nares screen in the ED and 79 patients did not. Median duration of antibiotic exposure was similar for both groups (No MRSA screen, 30.5 h [interquartile range (IQR) 20.5-52.5] vs. MRSA screen, 24.5 h [IQR 20.6-40.3]; p = 0.28). Of patients who were screened, 35 were negative and 2 were positive. Secondary outcomes were similar. CONCLUSION: Performing a MRSA nares screen in the ED for patients diagnosed with pneumonia, initiated on anti-MRSA antibiotics, and admitted to a general medicine floor did not decrease duration of anti-MRSA antibiotics. At this time, ED providers do not need to consider a MRSA nasal screen in the ED for patients being admitted to general medicine, although larger studies could be considered.
Asunto(s)
Servicio de Urgencia en Hospital , Tamizaje Masivo/métodos , Staphylococcus aureus Resistente a Meticilina , Cavidad Nasal/microbiología , Neumonía Estafilocócica/microbiología , Adulto , Anciano , Antibacterianos/uso terapéutico , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Linezolid/uso terapéutico , Masculino , Persona de Mediana Edad , Neumonía Estafilocócica/tratamiento farmacológico , Estudios Retrospectivos , Factores de Tiempo , Vancomicina/uso terapéuticoRESUMEN
Staphylococcus aureus is a leading cause of pneumonia. We show here that the ClpXP protease involved in protein turnover is important for pathogenesis in a murine model of acute pneumonia. Staphylococcus aureus lacking this protease is attenuated in vivo, being rapidly cleared from the airway and leading to decreased immune cell influx and inflammation. Characterization of defined mutations in vitro identified defects in intracellular survival and protection against neutrophil killing. Our results further expand on what is known about ClpXP in the pathogenesis of S. aureus to include the respiratory tract.
Asunto(s)
Proteínas Bacterianas/metabolismo , Endopeptidasa Clp/metabolismo , Neumonía Estafilocócica/microbiología , Staphylococcus aureus/patogenicidad , Animales , Proteínas Bacterianas/genética , Modelos Animales de Enfermedad , Endopeptidasa Clp/genética , Femenino , Interacciones Huésped-Patógeno , Inflamación , Masculino , Ratones , Ratones Endogámicos C57BL , Viabilidad Microbiana , Mutación , Neutrófilos/inmunología , Neumonía Estafilocócica/inmunología , Neumonía Estafilocócica/patología , Staphylococcus aureus/enzimología , Staphylococcus aureus/genéticaRESUMEN
Staphylococcus aureus is a leading cause of bacterial pneumonia, and we have shown previously that type I interferon (IFN) contributes to the pathogenesis of this disease. In this study, we screened 75 S. aureus strains for their ability to induce type I and III IFN. Both cytokine pathways were differentially stimulated by various S. aureus strains independently of their isolation sites or methicillin resistance profiles. These induction patterns persisted over time, and type I and III IFN generation differentially correlated with tumor necrosis factor alpha production. Investigation of one isolate, strain 126, showed a significant defect in type I IFN induction that persisted over several time points. The lack of induction was not due to differential phagocytosis, subcellular location, or changes in endosomal acidification. A correlation between reduced type I IFN induction levels and decreased autolysis and lysostaphin sensitivity was found between strains. Strain 126 had a decreased rate of autolysis and increased resistance to lysostaphin degradation and host cell-mediated killing. This strain displayed decreased virulence in a murine model of acute pneumonia compared to USA300 (current epidemic strain and commonly used in research) and had reduced capacity to induce multiple cytokines. We observed this isolate to be a vancomycin-intermediate S. aureus (VISA) strain, and reduced Ifnb was observed with a defined mutation in walK that induces a VISA phenotype. Overall, this study demonstrates the heterogeneity of IFN induction by S. aureus and uncovered an interesting property of a VISA strain in its inability to induce type I IFN production.
Asunto(s)
Citocinas/inmunología , Interferón Tipo I/inmunología , Infecciones Estafilocócicas/inmunología , Staphylococcus aureus/patogenicidad , Animales , Antibacterianos/farmacología , Carga Bacteriana , Proteínas Bacterianas/genética , Células Cultivadas , Farmacorresistencia Bacteriana/genética , Lisostafina/farmacología , Ratones , Pruebas de Sensibilidad Microbiana , Mutación , Neumonía Estafilocócica/inmunología , Neumonía Estafilocócica/microbiología , Transducción de Señal , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación , Vancomicina/farmacología , VirulenciaRESUMEN
Gram-positive bacteria, including Staphylococcus aureus are endemic in the U.S., which cause life-threatening necrotizing pneumonia. Neutrophils are known to be critical for clearance of S. aureus infection from the lungs and extrapulmonary organs. Therefore, we investigated whether the NLRP6 inflammasome regulates neutrophil-dependent host immunity during pulmonary S. aureus infection. Unlike their wild-type (WT) counterparts, NLRP6 knockout (KO) mice were protected against pulmonary S. aureus infection as evidenced by their higher survival rate and lower bacterial burden in the lungs and extrapulmonary organs. In addition, NLRP6 KO mice displayed increased neutrophil recruitment following infection, and when neutrophils were depleted the protective effect was lost. Furthermore, neutrophils from the KO mice demonstrated enhanced intracellular bacterial killing and increased NADPH oxidase-dependent ROS production. Intriguingly, we found higher NK cell-mediated IFN-γ production in KO mouse lungs, and treatment with IFN-γ was found to enhance the bactericidal ability of WT and KO neutrophils. The NLRP6 KO mice also displayed decreased pyroptosis and necroptosis in the lungs following infection. Blocking of pyroptosis and necroptosis in WT mice resulted in increased survival, reduced bacterial burden in the lungs, and attenuated cytokine production. Taken together, these novel findings show that NLRP6 serves as a negative regulator of neutrophil-mediated host defense during Gram-positive bacterial infection in the lungs through regulating both neutrophil influx and function. These results also suggest that blocking NLRP6 to augment neutrophil-associated bacterial clearance should be considered as a potential therapeutic intervention strategy for treatment of S. aureus pneumonia.
Asunto(s)
Infiltración Neutrófila/inmunología , Neumonía Estafilocócica/inmunología , Receptores de Superficie Celular/inmunología , Animales , Linfocitos T CD4-Positivos/inmunología , Femenino , Interacciones Huésped-Patógeno/inmunología , Humanos , Inflamasomas/inmunología , Interferón gamma/biosíntesis , Células Asesinas Naturales/inmunología , Pulmón/inmunología , Pulmón/microbiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neumonía Necrotizante/inmunología , Neumonía Necrotizante/microbiología , Neumonía Estafilocócica/microbiología , Piroptosis/inmunología , Especies Reactivas de Oxígeno/metabolismo , Receptores de Superficie Celular/deficiencia , Receptores de Superficie Celular/genética , Staphylococcus aureus/inmunología , Regulación hacia ArribaRESUMEN
Staphylococcus aureus is an emergent etiology of community-acquired pneumonia (CAP) over the past 2 decades, with severe community-acquired pneumonia (SCAP) caused by methicillin-resistant S. aureus (MRSA) leading to critical illness and death. S. aureus colonization is associated with a high incidence of pneumonia. Panton-Valentine leukocidin (PVL) is one of the most important virulence factors of S. aureus associated with serious complications. In recent years, community-associated MRSA (CA-MRSA) clones that caused infections in young adults and healthy individuals with no exposure to health care settings and no classical risk factors have emerged. Clinical features at admission including concurrent influenza infection, hemoptysis, multilobar infiltrates, and neutropenia should suggest S. aureus CAP. Sputum Gram stains, cultures (or tracheobronchial aspirates or bronchoalveolar lavage in mechanically ventilated patients), polymerase chain reaction (nasopharyngeal or oropharyngeal or lower respiratory tract specimens), and two sets of blood cultures should be obtained from patients presenting with severe S. aureus CAP. For CAP due to methicillin-susceptible S. aureus, first-line therapy is usually cefazolin, oxacillin, or ceftaroline. For CA-MRSA pneumonia, linezolid is recommended. If vancomycin or teicoplanin are used, combination with clindamycin or rifampicin should be considered in cases of PVL-positive MRSA CAP.
Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Comunitarias Adquiridas/epidemiología , Neumonía Estafilocócica/epidemiología , Staphylococcus aureus/efectos de los fármacos , Toxinas Bacterianas/sangre , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/microbiología , Exotoxinas/sangre , Humanos , Leucocidinas/sangre , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Neumonía Estafilocócica/tratamiento farmacológico , Neumonía Estafilocócica/microbiología , Factores de VirulenciaRESUMEN
P. petiolosa as a typical Chinese herbal medicine has been generally utilized as Chinese native medicine formulation for treatment of chronic bronchitis, bronchial asthma and pneumoconiosis. The objective of this study was to evaluate the anti-inflammatory and antibacterial activities of P. petiolosa ethyl acetate extract (PPEAE) against S. aureus in mice. The air-dried leaves were extracted with ethyl acetate, mice were infected pneumonia by S. aureus. Colonization of S. aureus in lung tissue was calculated by plate colony count. The number of white blood cells (WBC) in blood was measured by blood cell automatic analyzer. The histopathological analysis of hematoxylin-eosin staining (H&E) of lung tissue was observed under microscope. Real-time PCR assay was employed to determine the relative mRNA expression of HO-1, iNOS and TNF-α. The results showed that, compared with control, after treated with PPEAE the wet/dry (W/D) weight ratio of mice lung tissue (decreased from 5.371 to 4.9) and the number of white blood cells (WBC) (decreased by 3.13×109/mL) decreased dramatically. The number of S. aureus was significantly reduced (from 1.93×105 CFU/mL to 26×103 CFU/mL) in lung tissue after treated with PPEAE. Furthermore, H&E staining showed that PPEAE obviously relieved the inflammation of lung tissue of infected mice. Meanwhile, real-time PCR results indicated that PPEAE down regulated the expression of inflammatory iNOS, TNF-α mRNA and up regulated the expression of anti-inflammatory HO-1 mRNA. In summary, this study revealed that application of crude product PPEAE had prominent antibacterial activity against S. aureus. PPEAE significantly reduced the biomass of S. aureus in lung tissue and effectively relieved the inflammation of S. aureus-induced pneumonia.
Asunto(s)
Antibacterianos/farmacología , Antiinflamatorios/farmacología , Pulmón/efectos de los fármacos , Extractos Vegetales/farmacología , Neumonía Estafilocócica/tratamiento farmacológico , Polypodiaceae , Staphylococcus aureus/efectos de los fármacos , Acetatos/química , Animales , Antibacterianos/aislamiento & purificación , Antiinflamatorios/aislamiento & purificación , Carga Bacteriana , Modelos Animales de Enfermedad , Hemo-Oxigenasa 1/genética , Hemo-Oxigenasa 1/metabolismo , Mediadores de Inflamación/metabolismo , Pulmón/metabolismo , Pulmón/microbiología , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones Endogámicos BALB C , Óxido Nítrico Sintasa de Tipo II/genética , Óxido Nítrico Sintasa de Tipo II/metabolismo , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta , Neumonía Estafilocócica/metabolismo , Neumonía Estafilocócica/microbiología , Polypodiaceae/química , Solventes/química , Staphylococcus aureus/crecimiento & desarrollo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Methicillin-resistant Staphylococcus aureus (MRSA) is a versatile human pathogen that is associated with diverse types of infections ranging from benign colonization to sepsis. We postulated that MRSA must undergo specific genotypic and phenotypic changes to cause chronic pulmonary disease. We investigated how MRSA adapts to the human airway to establish chronic infection, as occurs during cystic fibrosis (CF). MRSA isolates from patients with CF that were collected over a 4-year period were analyzed by whole-genome sequencing, transcriptional analysis, and metabolic studies. Persistent MRSA infection was associated with staphylococcal metabolic adaptation, but not changes in immunogenicity. Adaptation was characterized by selective use of the tricarboxylic acid cycle cycle and generation of biofilm, a means of limiting oxidant stress. Increased transcription of specific metabolic genes was conserved in all host-adapted strains, most notably a 10,000-fold increase in fumC, which catalyzes the interconversion of fumarate and malate. Elevated fumarate levels promoted in vitro biofilm production in clinical isolates. Host-adapted strains preferred to assimilate glucose polymers and pyruvate, which can be metabolized to generate N-acetylglucosamine polymers that comprise biofilm. MRSA undergoes substantial metabolic adaptation to the human airway to cause chronic pulmonary infection, and selected metabolites may be useful therapeutically to inhibit infection.
Asunto(s)
Fibrosis Quística/microbiología , Enfermedades Pulmonares/microbiología , Staphylococcus aureus Resistente a Meticilina/metabolismo , Neumonía Estafilocócica/microbiología , Infecciones Estafilocócicas/microbiología , Acetilglucosamina/metabolismo , Adulto , Animales , Biopelículas , Bronquios/metabolismo , Líquido del Lavado Bronquioalveolar , Fibrosis Quística/metabolismo , Citocinas/metabolismo , Femenino , Fumaratos/metabolismo , Gentamicinas/farmacología , Glucosa/metabolismo , Humanos , Enfermedades Pulmonares/metabolismo , Malatos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Filogenia , Neumonía Estafilocócica/metabolismo , Ácido Pirúvico/metabolismo , Infecciones Estafilocócicas/metabolismo , Transcripción Genética , Ácidos Tricarboxílicos/metabolismo , Secuenciación Completa del GenomaRESUMEN
Postinfluenza methicillin-resistant Staphylococcus aureus (MRSA) infection can quickly develop into severe, necrotizing pneumonia, causing over 50% mortality despite antibiotic treatments. In this study, we investigated the efficacy of antibiotic therapies and the impact of S. aureus alpha-toxin in a model of lethal influenza virus and MRSA coinfection. We demonstrate that antibiotics primarily attenuate alpha-toxin-induced acute lethality, even though both alpha-toxin-dependent and -independent mechanisms significantly contribute to animal mortality after coinfection. Furthermore, we found that the protein synthesis-suppressing antibiotic linezolid has an advantageous therapeutic effect on alpha-toxin-induced lung damage, as measured by protein leak and lactate dehydrogenase (LDH) activity. Importantly, using a Panton-Valentine leucocidin (PVL)-negative MRSA isolate from patient sputum, we show that linezolid therapy significantly improves animal survival from postinfluenza MRSA pneumonia compared with vancomycin treatment. Rather than improved viral or bacterial control, this advantageous therapeutic effect is associated with a significantly attenuated proinflammatory cytokine response and acute lung damage in linezolid-treated mice. Together, our findings not only establish a critical role of alpha-toxin in the extreme mortality of secondary MRSA pneumonia after influenza but also provide support for the possibility that linezolid could be a more effective treatment than vancomycin to improve disease outcomes.
Asunto(s)
Antibacterianos/farmacología , Toxinas Bacterianas/antagonistas & inhibidores , Proteínas Hemolisinas/antagonistas & inhibidores , Linezolid/farmacología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Infecciones por Orthomyxoviridae/complicaciones , Neumonía Estafilocócica/tratamiento farmacológico , Animales , Toxinas Bacterianas/genética , Toxinas Bacterianas/metabolismo , Femenino , Expresión Génica , Gentamicinas/farmacología , Proteínas Hemolisinas/genética , Proteínas Hemolisinas/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Pulmón/microbiología , Pulmón/patología , Masculino , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Staphylococcus aureus Resistente a Meticilina/patogenicidad , Ratones , Ratones Endogámicos C57BL , Infecciones por Orthomyxoviridae/mortalidad , Infecciones por Orthomyxoviridae/patología , Infecciones por Orthomyxoviridae/virología , Plásmidos/química , Plásmidos/metabolismo , Neumonía Estafilocócica/complicaciones , Neumonía Estafilocócica/microbiología , Neumonía Estafilocócica/mortalidad , Análisis de Supervivencia , Vancomicina/farmacologíaRESUMEN
Background: Coinfection with influenza virus and methicillin-resistant Staphylococcus aureus (MRSA) causes life-threatening necrotizing pneumonia in children. Sporadic incidence precludes evaluation of antimicrobial efficacy. We assessed the clinical characteristics and outcomes of critically ill children with influenza-MRSA pneumonia and evaluated antibiotic use. Methods: We enrolled children (<18 years) with influenza infection and respiratory failure across 34 pediatric intensive care units 11/2008-5/2016. We compared baseline characteristics, clinical courses, and therapies in children with MRSA coinfection, non-MRSA bacterial coinfection, and no bacterial coinfection. Results: We enrolled 170 children (127 influenza A, 43 influenza B). Children with influenza-MRSA pneumonia (N = 30, 87% previously healthy) were older than those with non-MRSA (N = 61) or no (N = 79) bacterial coinfections. Influenza-MRSA was associated with increased leukopenia, acute lung injury, vasopressor use, extracorporeal life support, and mortality than either group (P ≤ .0001). Influenza-related mortality was 40% with MRSA compared to 4.3% without (relative risk [RR], 9.3; 95% confidence interval [CI], 3.8-22.9). Of 29/30 children with MRSA who received vancomycin within the first 24 hours of hospitalization, mortality was 12.5% (N = 2/16) if treatment also included a second anti-MRSA antibiotic compared to 69.2% (N = 9/13) with vancomycin monotherapy (RR, 5.5; 95% CI, 1.4, 21.3; P = .003). Vancomycin dosing did not influence initial trough levels; 78% were <10 µg/mL. Conclusions: Influenza-MRSA coinfection is associated with high fatality in critically ill children. These data support early addition of a second anti-MRSA antibiotic to vancomycin in suspected severe cases.
Asunto(s)
Antibacterianos/uso terapéutico , Coinfección/tratamiento farmacológico , Enfermedad Crítica , Gripe Humana/complicaciones , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Neumonía Estafilocócica/tratamiento farmacológico , Vancomicina/uso terapéutico , Adolescente , Niño , Preescolar , Coinfección/microbiología , Coinfección/mortalidad , Coinfección/patología , Femenino , Humanos , Lactante , Recién Nacido , Gripe Humana/mortalidad , Gripe Humana/patología , Masculino , Neumonía Estafilocócica/microbiología , Neumonía Estafilocócica/mortalidad , Neumonía Estafilocócica/patología , Estudios Prospectivos , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
The use of macrolides against pneumonia has been reported to improve survival; however, little is known about their efficacy against methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. In this study, we investigated the effect of azithromycin (AZM) and compared it with that of vancomycin (VCM) and daptomycin (DAP) in a murine model of MRSA pneumonia. Mice were infected with MRSA by intratracheal injection and then treated with AZM, VCM, or DAP. The therapeutic effect of AZM, in combination or not with the other drugs, was compared in vivo, whereas the effect of AZM on MRSA growth and toxin mRNA expression was evaluated in vitro. In vivo, the AZM-treated group showed significantly longer survival and fewer bacteria in the lungs 24 h after infection than the untreated group, as well as the other anti-MRSA drug groups. No significant decrease in cytokine levels (interleukin-6 [IL-6] and macrophage inflammatory protein-2 [MIP-2]) in bronchoalveolar lavage fluid or toxin expression levels (α-hemolysin [Hla] and staphylococcal protein A [Spa]) was observed following AZM treatment. In vitro, AZM suppressed the growth of MRSA in late log phase but not in stationary phase. No suppressive effect against toxin production was observed following AZM treatment in vitro In conclusion, contrary to the situation in vitro, AZM was effective against MRSA growth in vivo in our pneumonia model, substantially improving survival. The suppressive effect on MRSA growth at the initial stage of pneumonia could underlie the potential mechanism of AZM action against MRSA pneumonia.